chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 60-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: COVID 19 Treatment. Therapeutic measures were taken as a result of drug ineffective, covid-19.   Clinical information: Other medication in 2 weeks was none, patient was given Paxlovid as covid-19 treatment from 13Oct2022 to 18Oct2022.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Itchy red rash all over chest and left side of neck and left ear.; This is a spontaneous report from a contactable consumer or other non hcp. A 28-years-old non pregnant female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Lot/Batch number: EN6200, Pfizer NTEC), via an unspecified route of administration, administered in Arm Left on 03Mar2021 11:15 as, 2nd dose, single for covid-19 immunisation. Medical history included eczema, asthma (Patient stated It was Hereditary she was not on medication), penicillin allergy, ongoing blood cholesterol increased (Other Conditions: Yes). The patient previously took 1st dose of bnt162b2 (Lot: EL9264) on 06FEB2021 at 11:00 AM in the Left arm for COVID-19 immunisation and experienced rash near the injection site, amoxicillin and experienced allergic. Concomitant medications included salbutamol (ALBUTEROL), Ethinylestradiol, Norgestimate (TRI-PREVIFEM), Hydroxozine (strength 25 mg), and bupropion (strength 200 mg) taken for an unspecified indication, start and stop date were not reported. The patient experienced itchy red rash all over chest and left side of neck and left ear on 05Mar2021. The events assessed as serious (Medically significant). Treatment was received for the events, patient had allergy medicines, lotions but nothing is really helping and she had been taking BENADRYL, non Pfizer product (Lot Number: 032D9B, Expiry date: Nov 2021) but that hadn't been doing anything and then she was about to take Zyrtec. The patient underwent lab tests and procedures which included sars-cov-2 test: negative on 29Jan2021. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, was the patient did not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. Patient stated she hasn't if it really required me to went to the emergency room because she hasn't knew what they would tell me. I felt liked they'll have been liked took the lotion. No product complaint to be reported and medical information was requested. The outcome of the event was reported as not recovered on unknown date.  Follow-up attempts are needed. Further information is expected.
7-10 hours post vax pt experienced nausea, fever 102.2. Pt was weak and fell to knees - did not pass out.
This spontaneous report as received from a health care professional refers to a patient of 16 months old. On 01-JUL-2014 the patient was vaccinated with GARDASIL dose 1 (unknown route and dose). No adverse symptoms reported. Additional information has been requested.
It was reported that an 11-year old female pt received a flu vaccination. Two days after the vax the pt's feet started to go to sleep then her legs. The pt began having spasms in her back which have progressed severely to the point of becoming confined to a wheelchair. Further information requested.
Pt said within 90 minutes, she felt like she was getting a cold, headache, eyes hurt, hip & knee joints hurt, throat & nose got involved, sneezing. This lasted about 48 hours, then eased off. Now she is fine.
Kidney stone pain started 3 hours after vaccination.  Stone passed 8 hours later.  Only other stone was a small one 12 years prior.
Pfizer monovalent vaccine ordered by provider and administered by nursing staff when patient presented fro office visit on 8/18/22. Almost two months later, on 10/13/22, parents were in our office and brought in documentation that patient had received 2 prior Pfizer Covid vaccines, on 6/30/22 and 7/30/22.
This case was reported by a nurse via call center representative and described the occurrence of sunburn in a female patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, couple of days after receiving SHINGRIX, the patient experienced sunburn. On an unknown date, the outcome of the sunburn was unknown. It was unknown if the reporter considered the sunburn to be related to SHINGRIX. Additional details were reported as follows: The age at vaccination was not reported. The healthcare professional reported sunburn on both arms a few days after receiving SHINGRIX. The healthcare professional self-reported this adverse event on healthcare professional chat. The healthcare professional did not provide personal details or vaccine information in this chat.
Pt seen @ MD office 1PM 5AUG that evening mom states would wake up screaming & crying unconsolably-vomited x 3 p/nursing during the noc;
A few hours after the vaccine I developed arm soreness, nausea and stomach pains as if I had did 100 situps which lasted about 24 hours but the arm soreness lasted about 3 days and afterward all symptoms subsided
Vomiting; nausea; Pain at injection (L); This spontaneous case was reported by a consumer and describes the occurrence of VOMITING (Vomiting), NAUSEA (nausea) and VACCINATION SITE PAIN (Pain at injection (L)) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025J20A) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension. Concomitant products included MEPOLIZUMAB (NUCALA) from an unknown date to 11-Jan-2021 for Allergy, AMLODIPINE for Hypertension.    On 20-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Jan-2021, the patient experienced VACCINATION SITE PAIN (Pain at injection (L)). On 21-Jan-2021, the patient experienced VOMITING (Vomiting) and NAUSEA (nausea). On 21-Jan-2021, VACCINATION SITE PAIN (Pain at injection (L)) had resolved. At the time of the report, VOMITING (Vomiting) and NAUSEA (nausea) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications reported included [ Amlodipine and Nucala Auto Injector]  No treatment information was provided.
6FEB91 & pt exp extreme pharyngitis, severe upper resp infect, cough, shallow resp, & arthralgia;20MAR91 exp a prolonged upper resp infect & could not resume jogging for another 2wk;rt scotoma;had toxic optic neuropathy;OM & UTI
Site of injection (Left Upper Arm), there is now an infection where needle was inserted. Puss is noted along with redness and hard to touch. Approximately 1/4" in diameter
Received a spontaneous report on 23JAN2018 and 25JAN2018 from a MEDCOM personnel. The physician reported that on 23JAN2018, a member received 3ml of BIOTRHAX vaccine injected into the right deltoid rather than the prescribed 0.5ml amount. The subject experienced soreness at the site, and then developed mild headaches approximately 8 hours after the injection. No other complications were reported after 24 hours observation. The subject was restricted from caffeine and working out for the first 72 hours. It was also noted that he received a flu shot on 19DEC2017 and was on doxycycline for malaria prophylaxis. FOLLOW UP Information was received on 16FEB2018 from the physician. The physician reported that the patient was evaluated by medics and no evidence of lingering side effects was found. It was also noted that the patient felt excellent, had no signs of complications at the sight, and no signs or symptoms that would lead one to believe he is not in perfect/usual health. No additional information is expected.
Sore arm; This is a spontaneous report from a contactable consumer. This consumer reported similar events for three patients. This is the second of three reports. A patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number EK9231) via unspecified route of administration on 19Jan2021 at single dose for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. The patient experienced sore arm on 19Jan2021. The outcome of events was unknown.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021092694 same reporter/drug/event, different patient;US-PFIZER INC-2021092683 same reporter/drug, different patient/event
Left thigh swollen, red and hot, cool compresses Augmentin x 7 days.
This spontaneous case was initially received on 05-NOV-2015. The case report was received from a(n) Health Professional and concerns a(n) 21 year old female patient. Suspect drug(s), timing and conditions surrounding the onset of reaction(s)/event(s): The patient received AFLURIA on 05-NOV-2015 - unknown stop date, Batch no: U56807, Route of administration: Intramuscular, Dose: 0.5 ml. Additional suspect drug(s): No additional drugs suspected. Reaction(s)/event(s) outcome: On 05-NOV-2015 08:45, after starting/treatment with AFLURIA the patient experienced AFLURIA pre-filled syringe that was  left out for 8 hours and reached room temperature (first excursion) was administered (non serious, outcome: Unknown). On an unknown date, after starting/treatment with AFLURIA the patient experienced AFLURIA pre-filled syringe that was left out for 8 hours and reached room temperature (first excursion)/Temperature excursion occurred (non serious, outcome: Unknown). Reporter's assessment: Not reported.
Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 16-JUN-2011, a healthcare provider at a medical clinic administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On or about 03-SEP-2016, the patient was treated by a physician assistant at a medical center for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the zoster vaccine live (ZOSTAVAX) vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the zoster vaccine live (ZOSTAVAX) vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death; aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
1) There were no side effects after taking the first vaccine (except for pain on the left arm for 2 days) 2)  Until yesterday, there were no side effects after taking the second vaccine (except for pain on the left arm for 2-3 days) 3) Last night when I went to bed, I felt distinct pulling sensation of nerve on right side of the chin/jaw area. The pulling sensation is still present after 20 hours and can clearly be seen when I look at the mirror. I am not sure if this is early symptom of Bell's Palsy. 4) As of now, I do not seem to have any other side effects.
Pt had pain at the left deltoid at site of HPV vaccine. Mother is nervous about such a new vaccine MSM didn't really want this due to it not out in the community long enough. But we sent this anyway due to the pain at same muscle group.
Information has been received from a nurse concerning a 12 month old female who was vaccinated with a dose of ZOSTAVAX instead of a dose of VARIVAX.  No adverse reactions were reported.  There was no product quality complaint involved.  Additional information could not be obtained from the reporting nurse.  She indicated that she reported all the information about the patient via online and she refuse to provide any more information to us.  Additional information has been requested.
given DTP inject; mom reports that pt cried x 3 hrs p/inject; MD notified, suggested no more pertussis in immun;
Swelling, pain radiating from left deltoid to triceps area tightness and pressure at site with slight rash.
A report has been received from a Health Professional concerning a 7 year old, male subject, who had been receiving Nasal FLUMIST QUADRIVALENT. FLUMIST QUADRIVALENT (Intranasal) started on 23-Jan-2014. The patient was administered expired FLUMIST on 23-Jan-2014. The outcome of the event of expired FLUMIST is unknown. The report was considered to be non-serious.
Inappropriate schedule of vaccine received a 3rd dose of the primary series instead of the bivalent vaccine; 18 month old son probably received a 3rd dose of the primary series instead of the bivalent vaccine but the vaccination provider wasn't sure of this potential administration error; No Adverse Event; This spontaneous case was reported by a patient family member or friend and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine received a 3rd dose of the primary series instead of the bivalent vaccine), CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (18 month old son probably received a 3rd dose of the primary series instead of the bivalent vaccine but the vaccination provider wasn't sure of this potential administration error) and NO ADVERSE EVENT (No Adverse Event) in an 18-month-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. ASKU) for COVID-19 prophylaxis.     It was unknown regarding relevant medical history/conditions, allergy, concomitant diseases and risk factor.     On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine received a 3rd dose of the primary series instead of the bivalent vaccine), CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (18 month old son probably received a 3rd dose of the primary series instead of the bivalent vaccine but the vaccination provider wasn't sure of this potential administration error) and NO ADVERSE EVENT (No Adverse Event). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Inappropriate schedule of vaccine received a 3rd dose of the primary series instead of the bivalent vaccine), CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR (18 month old son probably received a 3rd dose of the primary series instead of the bivalent vaccine but the vaccination provider wasn't sure of this potential administration error) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.            No concomitant medications details were reported.  It was unknown if patient received vaccines in the 4 weeks prior to COVID-19 vaccine. Moderna was not authorized to communicate with the vaccine recipient's primary healthcare professional regarding this notification. Safety team did not had consent for follow-up. Caregiver stated her 18 month old son probably received a third dose of the primary series instead of the bivalent vaccine but the vaccination provider wasn't sure of this potential administration error. There are no additional details available. It was unknown if the patient experienced any AEs.  No treatment medications details were reported.
pain at the injection site after the injection, and this pain went from injection site straight to her elbow; This non-serious case was reported by a physician via sales rep and described the occurrence of pain in arm in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 04-JUL-2023, the patient received the 1st dose of Shingrix (intramuscular, left arm). On 04-JUL-2023, immediately after receiving Shingrix, the patient experienced pain in arm (Verbatim: pain at the injection site after the injection, and this pain went from injection site straight to her elbow). The outcome of the pain in arm was not resolved.   It was unknown if the reporter considered the pain in arm to be related to Shingrix.     It was unknown if the company considered the pain in arm to be related to Shingrix.   Additional Information: GSK receipt date: 8-Sept-2023 A physician stated in his office on the day of reporting, the patient in her early 60's received the 1st dose of Shingrix around 4th July 2023, at her pharmacy, and immediately had really bad pain at the injection site after the injection, and this pain went from the injection site straight to her elbow. The patient still had this same pain, in the same area on the day of reporting. The GlaxoSmithKline field representative did not had any further information about this incident, any information about the lot/expiry, or any patient demographics. The reporter consented to follow-up.
APPROXIMATELY 10-15 MINUTES AFTER VACCINE ADMINISTRATION, PATIENT TURNED RED, STARTED SCRATCHING AT HER THROAT, GOT BLUE AROUND THE LIPS.  PULSE OX WAS IN THE 80S.  EMS WAS CALLED.  OX AND BENADRYL GIVEN.
A report was received from a health care professional on 11/24/03 concerning a 52 year old female vaccinee who inadvertently received expired Fluvirin vaccine on 11/10/03 approximately. On 11/10/03 approximately, the vaccinee inadvertently received expired Fluvirin. It was not reported if the vaccinee had experienced any adverse reaction. There was insufficient information to determine the reporter's causality assessment. Follow up pending.
headache; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (headache) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 043L20A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high and Anxiety. Concomitant products included FLUOXETINE HYDROCHLORIDE (PROZAC) for Anxiety, ATORVASTATIN for Cholesterol, AMLODIPINE for Hypertension, TACROLIMUS MONOHYDRATE (TACROLIMUS [TACROLIMUS MONOHYDRATE]) for Kidney transplant.    On 24-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Jan-2021, the patient experienced HEADACHE (headache). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. On 25-Jan-2021, HEADACHE (headache) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       Concomitant medications reported were, second medication for anti rejection for kidney transplant, med for allergies.
Itchy throat; Swollen tongue; This is a spontaneous report from a non-contactable consumer or other non hcp. A 29-years-old female patient received bnt162b2 (BNT162B2, Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date as (at the age of 29 years) DOSE NUMBER UNKNOWN, SINGLE for covid-19 immunisation the patient was not diagnosed and didn't get tested with COVID-19 prior to vaccination. The patient medical history and concomitant medications were not reported. On an unspecified date the patient experienced itchy throat, swollen tongue patient did not had emergency room visit or physician office for these events. The outcome of the events throat irritation, swollen tongue was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.  Amendment: This follow-up report is being submitted to amend previously reported information Final sentence "Information about lot/batch number cannot be obtained. No further information is expected." updated as "No follow-up attempts are possible; information about lot/batch number cannot be obtained." Initial information need review for adverse events Itchy throat, swollen tongue. Outcome of the events was reported as unknown, patient did not received any treatment for the adverse events.
1 day p/vax pt devel an inj site rxn characterized by redness, warmth, & swelling;this is one of three employees from this site to devel an inj site rxn p/vax;
Patient given PNEUMOVAX 23 on 9/23/15. Later that day, I developed redness in arm and was sent for admission. Treated as local reaction with cellulitis. On 9/30/15, developed (L) facial droop consistent with Bells Palsy. Treated with steroids and antivirals. Symptoms persist at time of report.
Time and date above are when it was first noticed. Unsure of exact onset. Fluid filled blister at injection site is what was noted.
Covid19 Moderna Vaccine: throat itching, facial flushing, "cotton ball" in throat, left chest tightness, diphenhydramine at 2:07pm, reclined, 30 mins observation. resolved
Rash on face, neck, arms - dizziness, tightening in the throat - sweating.
Large hive hot sore at injection site. Approximately 5 inches one week AFTER injection
This spontaneous report as received from a physician refers to a patient of unknown age. The patient had no pertinent medical history and no drug reactions or allergies. The patient was vaccinated with PNEUMOVAX 23 (lot number reported as H013847, expired date 15-MAR-2014) (dose, frequency and injection site were not reported) intramuscular injection on an unknown date in October 2012 (within the past ten days). No other co-suspects were reported. There was no concomitant medication. The physician reported that he saw that patient the day after vaccination and that the patient presented with swelling of the upper arm in the mid-bicep region, warmth (lithe area was hot to the touch"), tenderness and pan. The patient started on unspecified antibiotics and mild analgesics. The patient was recovering at the time of report. There was no laboratory diagnostics studies performed. The patient had an office visit for medical attention. There was no laboratory diagnostics studies performed. Physician requests a lot check for the PNEUMOVAX 23. This is one of several reports received from the same source. Additional information has been requested.
pt devel h/a, body ache, T104, joint pain, cough, congestion;
First four or five days, I intermittently had a headache.  Took aspirin.  COVID Arm - My arm started with an itchy, small crusty rash.  About Day 5 or 6, I realized I had a significant red rash.  Roughly 6 or 7 inches top to bottom, and 3 to 4 inches left to right.  It matured and became "ripe."  It went away about a week later.
Headache 4 days, Fatigue 4 days, Rash X3 weeks, and Dizziness 4 days
ACCORDING TO RECORD, CLIENT RECEIVED 2 MODERNA DOSES FROM DR. ON 1/8/2021 AND 2/8/2021 AND THEN RECEIVED A SECOND MODERNA SERIES STARTING 2 MONTHS LATER ON 4/1/2021  WITH SECOND DOSE ON 5/1/2021.